Literature DB >> 7531423

Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting.

R G Speekenbrink1, A B Vonk, C R Wildevuur, L Eijsman.   

Abstract

Sixty patients (four groups of 15 patients) were entered in a randomized, controlled study to compare the efficacy of prophylactic treatment with dipyridamole, tranexamic acid, and aprotinin to reduce bleeding after elective coronary artery bypass grafting. Only patients with a preoperative platelet count of less than 246 x 10(9)/L were selected because a previous study showed that these individuals are at risk for increased postoperative bleeding. Compared to control subjects, postoperative blood loss 6 hours after operation was significantly reduced by tranexamic acid (674 +/- 411 versus 352 +/- 150 mL; p < 0.05) and by aprotinin (270 +/- 174 mL; p < 0.01). Dipyridamole did not reduce postoperative blood loss and was associated with complications in 3 patients. We conclude that hemostasis after cardiac operations can be improved with tranexamic acid and aprotinin. Dipyridamole appeared to be ineffective.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531423     DOI: 10.1016/0003-4975(94)00865-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

Review 1.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

2.  Unaccounted blood loss in operations using cardiopulmonary bypass.

Authors:  A Romagnoli; T B Stafford; A S Keats
Journal:  Tex Heart Inst J       Date:  1997

Review 3.  Tranexamic acid: a review of its use in surgery and other indications.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

4.  Risk Factors of Red Blood Cell Transfusion in Isolate off Pump Coronary Artery Bypass Surgery.

Authors:  Eui Suk Chung; Kay-Hyun Park; Cheong Lim; Jinho Choi
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-10-09

5.  Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.

Authors:  Isabel Taeuber; Stephanie Weibel; Eva Herrmann; Vanessa Neef; Tobias Schlesinger; Peter Kranke; Leila Messroghli; Kai Zacharowski; Suma Choorapoikayil; Patrick Meybohm
Journal:  JAMA Surg       Date:  2021-04-14       Impact factor: 14.766

Review 6.  Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

Review 7.  Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.

Authors:  Katharine Ker; Phil Edwards; Pablo Perel; Haleema Shakur; Ian Roberts
Journal:  BMJ       Date:  2012-05-17

8.  Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.

Authors:  Paul A Carless; Annette J Moxey; Barrie J Stokes; David A Henry
Journal:  BMC Cardiovasc Disord       Date:  2005-07-04       Impact factor: 2.298

9.  The safety and efficiency of intravenous administration of tranexamic acid in coronary artery bypass grafting (CABG): a meta-analysis of 28 randomized controlled trials.

Authors:  Yanting Zhang; Yun Bai; Minmin Chen; Youfa Zhou; Xin Yu; Haiyan Zhou; Gang Chen
Journal:  BMC Anesthesiol       Date:  2019-06-14       Impact factor: 2.217

10.  Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials.

Authors:  Jingfei Guo; Xurong Gao; Yan Ma; Huran Lv; Wenjun Hu; Shijie Zhang; Hongwen Ji; Guyan Wang; Jia Shi
Journal:  BMC Anesthesiol       Date:  2019-07-15       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.